Image source: The Motley Fool. Mirum Pharmaceuticals (NASDAQ:MIRM) reported record quarterly revenue growth and raised its full-year guidance, citing solid commercial execution and new regulatory ...
Hello everyone, and welcome to the Mirum Pharmaceuticals' Third Quarter 2024 Financial Results and Business Update. My name is Seb [ph] and I'll be the operator for your call today. [Operator ...
Management expects completion of VISTAS study enrollment for Volixibat in PSC in the third quarter of 2025, with data readout expected in the second quarter of 2026. Recently approved CTEXLI is ...
Mirum Pharmaceuticals(NASDAQ:MIRM) reported full-year revenue growth of 55%, driven by Livmarli uptake and strong bile acid medicine sales. A surge in R&D investment is planned for 2026, with ...
Operator: Hello and welcome to Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results. My name is Carla, and I’ll be coordinating your call today. [Operator Instructions] I would now like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results